Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.

Eriksson C, Henriksson I, Brus O, Zhulina Y, Nyhlin N, Tysk C, Montgomery S, Halfvarson J.

Aliment Pharmacol Ther. 2018 Sep;48(6):638-645. doi: 10.1111/apt.14920. Epub 2018 Aug 1.

2.

Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.

Wickbom A, Bohr J, Nyhlin N, Eriksson A, Lapidus A, Münch A, Ung KA, Vigren L, Öst Å, Tysk C; Swedish Organisation for the Study of Inflammatory Bowel Disease (SOIBD).

Scand J Gastroenterol. 2018 Apr;53(4):410-416. doi: 10.1080/00365521.2018.1430252. Epub 2018 Mar 16.

PMID:
29546806
3.

Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.

Wickbom A, Nyhlin N, Montgomery SM, Bohr J, Tysk C.

Eur J Gastroenterol Hepatol. 2017 May;29(5):587-594. doi: 10.1097/MEG.0000000000000832.

PMID:
28350750
4.

A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn's Disease.

Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F.

Inflamm Bowel Dis. 2017 Jan;23(1):133-142. doi: 10.1097/MIB.0000000000000988. Review.

PMID:
28002130
5.

Development of an index to define overall disease severity in IBD.

Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L.

Gut. 2018 Feb;67(2):244-254. doi: 10.1136/gutjnl-2016-312648. Epub 2016 Oct 25.

PMID:
27780886
6.

Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease - authors' reply.

Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J.

Aliment Pharmacol Ther. 2016 Oct;44(7):770-1. doi: 10.1111/apt.13767. No abstract available.

7.

Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study.

Oxelmark L, Lindberg A, Löfberg R, Sternby B, Eriksson A, Almer S, Befrits R, Fossum B, Karlén P, Broström O, Tysk C; SOIBD, the Swedish Organization for the study of Inflammatory Bowel Disease.

Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1320-8. doi: 10.1097/MEG.0000000000000710.

8.

The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.

Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J.

Aliment Pharmacol Ther. 2016 Sep;44(5):495-504. doi: 10.1111/apt.13731. Epub 2016 Jul 12.

9.

Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease.

Amcoff K, Joossens M, Pierik MJ, Jonkers D, Bohr J, Joossens S, Romberg-Camps M, Nyhlin N, Wickbom A, Rutgeerts PJ, Tysk C, Bodin L, Colombel JF, Vermeire S, Halfvarson J.

J Crohns Colitis. 2016 Jun;10(6):695-702. doi: 10.1093/ecco-jcc/jjw021. Epub 2016 Jan 27.

PMID:
26818662
10.

Smoking Status Influences Clinical Outcome in Collagenous Colitis.

Münch A, Tysk C, Bohr J, Madisch A, Bonderup OK, Mohrbacher R, Mueller R, Greinwald R, Ström M, Miehlke S.

J Crohns Colitis. 2016 Apr;10(4):449-54. doi: 10.1093/ecco-jcc/jjv235. Epub 2015 Dec 30.

11.

The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Örebro, Sweden 1963-2005.

Zhulina Y, Udumyan R, Tysk C, Montgomery S, Halfvarson J.

Scand J Gastroenterol. 2016 Mar;51(3):304-13. doi: 10.3109/00365521.2015.1093167. Epub 2015 Oct 7.

PMID:
26448101
12.

Enhanced levels of chemokines and their receptors in the colon of microscopic colitis patients indicate mixed immune cell recruitment.

Günaltay S, Kumawat AK, Nyhlin N, Bohr J, Tysk C, Hultgren O, Hultgren Hörnquist E.

Mediators Inflamm. 2015;2015:132458. doi: 10.1155/2015/132458. Epub 2015 Apr 9.

13.

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.

Münch A, Bohr J, Miehlke S, Benoni C, Olesen M, Öst Å, Strandberg L, Hellström PM, Hertervig E, Armerding P, Stehlik J, Lindberg G, Björk J, Lapidus A, Löfberg R, Bonderup O, Avnström S, Rössle M, Dilger K, Mueller R, Greinwald R, Tysk C, Ström M; BUC-63 investigators.

Gut. 2016 Jan;65(1):47-56. doi: 10.1136/gutjnl-2014-308363. Epub 2014 Nov 25.

14.

An in vitro model to evaluate the impact of the soluble factors from the colonic mucosa of collagenous colitis patients on T cells: enhanced production of IL-17A and IL-10 from peripheral CD4⁺ T cells.

Kumawat AK, Nyhlin N, Wickbom A, Tysk C, Bohr J, Hultgren O, Hörnquist EH.

Mediators Inflamm. 2014;2014:879843. doi: 10.1155/2014/879843. Epub 2014 Sep 21.

15.

Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis.

Günaltay S, Nyhlin N, Kumawat AK, Tysk C, Bohr J, Hultgren O, Hultgren Hörnquist E.

World J Gastroenterol. 2014 Sep 14;20(34):12249-59. doi: 10.3748/wjg.v20.i34.12249.

16.

Diagnosis and management of microscopic colitis: current perspectives.

Bohr J, Wickbom A, Hegedus A, Nyhlin N, Hultgren Hörnquist E, Tysk C.

Clin Exp Gastroenterol. 2014 Aug 21;7:273-84. doi: 10.2147/CEG.S63905. eCollection 2014. Review.

17.

Temporal trends in non-stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study.

Zhulina Y, Udumyan R, Henriksson I, Tysk C, Montgomery S, Halfvarson J.

J Crohns Colitis. 2014 Dec;8(12):1653-60. doi: 10.1016/j.crohns.2014.07.006. Epub 2014 Aug 10.

PMID:
25113899
18.

Letter: Persisting clinical symptoms in microscopic colitis in remission--authors' reply.

Nyhlin N, Wickbom A, Montgomery SM, Tysk C, Bohr J.

Aliment Pharmacol Ther. 2014 Jul;40(1):118. doi: 10.1111/apt.12810. No abstract available.

19.

Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study.

Nyhlin N, Wickbom A, Montgomery SM, Tysk C, Bohr J.

Aliment Pharmacol Ther. 2014 May;39(9):963-72. doi: 10.1111/apt.12685. Epub 2014 Mar 11.

20.

Letter: infliximab in severe ulcerative colitis - is it useful for all patients? Authors' reply.

Sjöberg M, Halfvarson J, Tysk C.

Aliment Pharmacol Ther. 2013 Dec;38(11-12):1413-4. doi: 10.1111/apt.12521. No abstract available.

21.

Lack of effect of methotrexate in budesonide-refractory collagenous colitis.

Münch A, Bohr J, Vigren L, Tysk C, Ström M.

Clin Exp Gastroenterol. 2013 Aug 30;6:149-52. doi: 10.2147/CEG.S48201. eCollection 2013.

22.

Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of Crohn's Disease.

Fransén K, Franzén P, Magnuson A, Elmabsout AA, Nyhlin N, Wickbom A, Curman B, Törkvist L, D'Amato M, Bohr J, Tysk C, Sirsjö A, Halfvarson J.

PLoS One. 2013 Aug 19;8(8):e72739. doi: 10.1371/journal.pone.0072739. eCollection 2013.

23.
24.

Analysis of single nucleotide polymorphisms in the region of CLDN2-MORC4 in relation to inflammatory bowel disease.

Söderman J, Norén E, Christiansson M, Bragde H, Thiébaut R, Hugot JP, Tysk C, O'Morain CA, Gassull M, Finkel Y, Colombel JF, Lémann M, Almer S.

World J Gastroenterol. 2013 Aug 14;19(30):4935-43. doi: 10.3748/wjg.v19.i30.4935.

25.

Stable incidence of collagenous colitis and lymphocytic colitis in Örebro, Sweden, 1999-2008: a continuous epidemiologic study.

Wickbom A, Bohr J, Eriksson S, Udumyan R, Nyhlin N, Tysk C.

Inflamm Bowel Dis. 2013 Oct;19(11):2387-93. doi: 10.1097/MIB.0b013e31829ed8cd.

PMID:
23945183
26.

Celiac disease and other autoimmune diseases in patients with collagenous colitis.

Vigren L, Tysk C, Ström M, Kilander AF, Hjortswang H, Bohr J, Benoni C, Larson L, Sjöberg K.

Scand J Gastroenterol. 2013 Aug;48(8):944-50. doi: 10.3109/00365521.2013.805809. Epub 2013 Jun 26.

PMID:
23800241
27.

Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients.

Sjöberg M, Magnuson A, Björk J, Benoni C, Almer S, Friis-Liby I, Hertervig E, Olsson M, Karlén P, Eriksson A, Midhagen G, Carlson M, Lapidus A, Halfvarson J, Tysk C; Swedish Organization for the Study of Inflammatory Bowel Disease (SOIBD).

Aliment Pharmacol Ther. 2013 Aug;38(4):377-87. doi: 10.1111/apt.12387. Epub 2013 Jun 25.

28.

Subclinical inflammation with increased neutrophil activity in healthy twin siblings reflect environmental influence in the pathogenesis of inflammatory bowel disease.

Zhulina Y, Hahn-Strömberg V, Shamikh A, Peterson CG, Gustavsson A, Nyhlin N, Wickbom A, Bohr J, Bodin L, Tysk C, Carlson M, Halfvarson J.

Inflamm Bowel Dis. 2013 Jul;19(8):1725-31. doi: 10.1097/MIB.0b013e318281f2d3.

PMID:
23669399
29.

Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile.

Kumawat AK, Strid H, Tysk C, Bohr J, Hörnquist EH.

Mol Immunol. 2013 Oct;55(3-4):355-64. doi: 10.1016/j.molimm.2013.03.007. Epub 2013 Apr 6.

PMID:
23566938
30.

Immunohistochemical characterization of lymphocytes in microscopic colitis.

Göranzon C, Kumawat AK, Hultgren-Hörnqvist E, Tysk C, Eriksson S, Bohr J, Nyhlin N.

J Crohns Colitis. 2013 Nov;7(10):e434-42. doi: 10.1016/j.crohns.2013.02.007. Epub 2013 Mar 19.

PMID:
23523417
31.

Letter: the impact of smoking on clinical outcomes after endoscopic dilatation in Crohn's disease - authors' reply.

Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C.

Aliment Pharmacol Ther. 2013 Feb;37(4):500-1. doi: 10.1111/apt.12213. No abstract available.

32.

Geographical variability and environmental risk factors in inflammatory bowel disease.

Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, O'Morain C, Moum B, Colombel JF; Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD).

Gut. 2013 Apr;62(4):630-49. doi: 10.1136/gutjnl-2012-303661. Epub 2013 Jan 18. Review.

PMID:
23335431
33.

Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease.

Erickson AR, Cantarel BL, Lamendella R, Darzi Y, Mongodin EF, Pan C, Shah M, Halfvarson J, Tysk C, Henrissat B, Raes J, Verberkmoes NC, Fraser CM, Hettich RL, Jansson JK.

PLoS One. 2012;7(11):e49138. doi: 10.1371/journal.pone.0049138. Epub 2012 Nov 28.

34.

Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease.

Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C.

Aliment Pharmacol Ther. 2013 Feb;37(4):430-7. doi: 10.1111/apt.12176. Epub 2012 Dec 3.

35.

Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells.

Kumawat AK, Strid H, Elgbratt K, Tysk C, Bohr J, Hultgren Hörnquist E.

J Crohns Colitis. 2013 Oct;7(9):694-705. doi: 10.1016/j.crohns.2012.08.014. Epub 2012 Sep 18.

PMID:
22995775
36.

Increased prevalence of antibodies against dietary proteins in children and young adults with cerebral palsy.

Stenberg R, Dahle C, Magnuson A, Hellberg D, Tysk C.

J Pediatr Gastroenterol Nutr. 2013 Feb;56(2):233-8. doi: 10.1097/MPG.0b013e318272cbf4.

PMID:
22983381
37.

Letter: endoscopic balloon dilatation or strictureplasty for stricturing Crohn's disease? Authors' reply.

Gustavsson A, Blomberg B, Andersson M, Halfvarson J, Tysk C.

Aliment Pharmacol Ther. 2012 Aug;36(4):404. doi: 10.1111/j.1365-2036.2012.05203.x. No abstract available.

38.

Elution of antitransglutaminase antibodies from duodenal biopsies: a novel approach in the diagnosis of celiac disease.

Rathsman S, Tysk C, Eriksson S, Hultgren O, Aberg AK, Olcén P.

APMIS. 2012 Aug;120(8):666-74. doi: 10.1111/j.1600-0463.2012.02884.x. Epub 2012 Mar 24.

PMID:
22779690
39.

Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group.

Münch A, Aust D, Bohr J, Bonderup O, Fernández Bañares F, Hjortswang H, Madisch A, Munck LK, Ström M, Tysk C, Miehlke S; European Microscopic Colitis Group (EMCG).

J Crohns Colitis. 2012 Oct;6(9):932-45. Epub 2012 Jun 15. Review.

40.

Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease.

Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C.

Aliment Pharmacol Ther. 2012 Jul;36(2):151-8. doi: 10.1111/j.1365-2036.2012.05146.x. Epub 2012 May 22.

41.

Is smoking a risk factor for collagenous colitis?

Vigren L, Sjöberg K, Benoni C, Tysk C, Bohr J, Kilander A, Larsson L, Ström M, Hjortswang H.

Scand J Gastroenterol. 2011 Nov;46(11):1334-9. doi: 10.3109/00365521.2011.610005. Epub 2011 Aug 19.

PMID:
21854096
42.

Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease.

Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H.

Eur J Gastroenterol Hepatol. 2011 Aug;23(8):671-9. doi: 10.1097/MEG.0b013e328346f622.

PMID:
21654323
43.

Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.

Eriksson C, Gustavsson A, Kronvall T, Tysk C.

J Gastrointestin Liver Dis. 2011 Mar;20(1):77-80. Review.

44.

Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.

Sjöberg M, Walch A, Meshkat M, Gustavsson A, Järnerot G, Vogelsang H, Hertervig E, Novacek G, Friis-Liby I, Blomquist L, Angelberger S, Karlen P, Grännö C, Vilien M, Ström M, Verbaan H, Hellström PM, Dejaco C, Magnuson A, Halfvarson J, Reinisch W, Tysk C.

Inflamm Bowel Dis. 2012 Feb;18(2):212-8. doi: 10.1002/ibd.21680. Epub 2011 Mar 15.

PMID:
21438096
45.

Recent advances in diagnosis and treatment of microscopic colitis.

Tysk C, Wickbom A, Nyhlin N, Eriksson S, Bohr J.

Ann Gastroenterol. 2011;24(4):253-262. Review.

46.

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease.

Momozawa Y, Mni M, Nakamura K, Coppieters W, Almer S, Amininejad L, Cleynen I, Colombel JF, de Rijk P, Dewit O, Finkel Y, Gassull MA, Goossens D, Laukens D, Lémann M, Libioulle C, O'Morain C, Reenaers C, Rutgeerts P, Tysk C, Zelenika D, Lathrop M, Del-Favero J, Hugot JP, de Vos M, Franchimont D, Vermeire S, Louis E, Georges M.

Nat Genet. 2011 Jan;43(1):43-7. doi: 10.1038/ng.733. Epub 2010 Dec 12.

47.

Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.

Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Verbaan H, Hellström PM, Magnuson A, Halfvarson J, Tysk C.

Aliment Pharmacol Ther. 2010 Oct;32(8):984-9. doi: 10.1111/j.1365-2036.2010.04435.x. Epub 2010 Aug 18.

48.

A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes.

Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L.

Gastroenterology. 2010 Dec;139(6):1844-1854.e1. doi: 10.1053/j.gastro.2010.08.049. Epub 2010 Oct 8.

PMID:
20816835
49.

RIP2 polymorphisms in inflammatory bowel diseases.

Thiébaut R, Douchin V, Jung C, Merlin F, Colombel JF, Lemann M, Almer S, Tysk C, O'Morain C, Gassull M, Finkel Y, Zouali H, Pascoe L, Hugot JP.

Inflamm Bowel Dis. 2011 Apr;17(4):1055. doi: 10.1002/ibd.21406. No abstract available.

PMID:
20645315
50.

Health-related quality of life is impaired in active collagenous colitis.

Hjortswang H, Tysk C, Bohr J, Benoni C, Vigren L, Kilander A, Larsson L, Taha Y, Ström M.

Dig Liver Dis. 2011 Feb;43(2):102-9. doi: 10.1016/j.dld.2010.06.004. Epub 2010 Jul 17.

PMID:
20638918

Supplemental Content

Support Center